Tianjin Tianyao Pharmaceutical Co., Ltd. – Market Snapshot and Context
Tianjin Tianyao Pharmaceutical Co., Ltd. (stock code 600488.SS) concluded its trading day on Thursday, 22 October 2026, at CNY 5.27 per share, exhibiting a flat 0 % change over the 24‑hour period that ended at 19:14 Central Europe time. The share price has stabilized after a recent decline, and the company’s liquidity remains robust with 1.1 billion shares available on the market.
Market Capitalization and Trading Volume
- Market Capitalization: Approximately CNY 6 billion.
- 24‑hour Trading Volume: Roughly CNY 280.9 million worth of shares changed hands.
- Average Price Over the Last 200 Days: The simple moving average sits at CNY 5.53, indicating a slight upward drift from the current price.
Performance Trends
- The stock has fallen –10.77 % since the close of last month, reflecting broader market volatility and sector‑specific pressures.
- Within the past 52 weeks, Tianjin Tianyao’s highest recorded price reached CNY 8.44 on 8 April 2026, while the lowest dipped to CNY 3.68 on 23 March 2026. These extremes illustrate the stock’s sensitivity to both internal developments and macro‑economic factors.
Peer Comparison
In the same trading window, several peer companies displayed varied movements:
| Company | Symbol | 24‑hour Change | Current Price | Market Capitalization | Notes |
|---|---|---|---|---|---|
| Doushen Beijing Education | 300010.SZ | 0 % | CNY 3.40 | CNY 7.1 billion | Flat |
| Hitevision | 002955.SZ | 0 % | CNY 29.12 | CNY 7.1 billion | P/E ratio 430.33 |
| Nanjing Leads Biolabs L‑h | 9887.HK | –7.03 % | HKD 36.96 | HKD 8.4 billion | Downward |
| Jiangsu Kanion Pharmaceutical | 600557.SS | 0 % | CNY 12.57 | CNY 7.1 billion | P/E ratio 23.14 |
| Shanghai Haixin | 600851.SS | 0 % | CNY 8.72 | CNY 7.1 billion | P/E ratio 54.03 |
The comparative table underscores that while Tianjin Tianyao’s price remained unchanged, some peers experienced significant fluctuations, particularly in the pharmaceutical and education sectors.
Company Profile
Tianjin Tianyao Pharmaceutical Co., Ltd. is headquartered in Tianjin, China, and specializes in the research, development, and manufacturing of corticoid and cardiovascular drugs. Its product portfolio includes:
- Drug Preparations – Both Western pharmaceuticals and traditional Chinese medicine formulations.
- Chinese Medicinal Crops – Cultivation and supply of medicinal herbs.
- Chinese Patent Drugs – Proprietary formulations protected by patents.
- Health Care Products – Over‑the‑counter supplements and wellness items.
- Injections – Injectable medications for various therapeutic indications.
In addition to manufacturing, Tianjin Tianyao offers technology consulting services, supporting other firms in product development and regulatory compliance. The company has been listed on the Shanghai Stock Exchange since its IPO on 24 May 2001 and maintains an online presence at www.tygf-jy.com .
Conclusion
Tianjin Tianyao Pharmaceutical’s recent flat performance, coupled with its substantial market capitalization and steady liquidity, positions it as a stable yet responsive player in China’s pharmaceutical landscape. Investors and industry observers will likely monitor upcoming earnings reports and regulatory announcements for further insight into the company’s trajectory amid a competitive market environment.
